Patients with ocular myasthenia gravis (MG) may have better long-term outcomes if they undergo thymectomy before their disease spreads to other muscles, according to a study published recently in the Journal of Clinical Medicine.
In this multicenter study of 174 patients, those who had surgery while symptoms were still limited to the eyes achieved higher remission rates and faced fewer neurological complications than patients who developed generalized ocular MG before surgery.
“Thymectomy performed during the purely ocular stage of MG is associated with higher rates of long-term remission and lower perioperative neurological risk compared to surgery after secondary generalization,” explained this study’s authors. “Minimally invasive approaches may broaden surgical eligibility by reducing procedural morbidity.”
This study found that 23.2% of patients in the ocular MG group reached complete stable remission compared with 11.3% in the generalized ocular MG group. Over five years, the probability of remission was nearly twice as high for patients who underwent surgery early, at 43% versus 22%. None of the patients in the ocular MG group experienced a postoperative myasthenic crisis, while 8.1% of those with generalized disease did.
Read more about treatment and care for MG
For patients without a thymoma, or tumor of the thymus gland, the results were similar: a 41% five-year remission rate for ocular MG versus 17% for generalized ocular MG. These results support earlier surgical consideration for selected patients, as delaying thymectomy until after generalization may reduce the chance of remission.
An additional factor influencing remission was medication use before surgery. Patients who were taking only cholinesterase inhibitors before thymectomy were far more likely to achieve remission. This treatment pattern emerged as a strong independent predictor of success, suggesting that managing symptoms with this single therapy before surgery may optimize surgical benefit.
The vast majority of surgeries, nearly 80%, were performed using minimally invasive or robotic-assisted techniques, resulting in low complication rates of just 5.2% and no deaths. Average hospital stays lasted about four days. These results underscore the safety of modern thymectomy approaches and the potential for faster recovery and reduced risk.
For patients, these findings suggest that considering thymectomy earlier in the disease course could improve long-term quality of life, limit disease spread and increase the chance of remission. With advancements in minimally invasive surgery and careful preoperative treatment, early thymectomy offers a safer and more effective option for people with ocular MG.
Sign up here to get the latest news, perspectives, and information about MG sent directly to your inbox. Registration is free and only takes a minute.
